Bristol Myers Squibb (BMY) Gains from Investment Securities (2010 - 2026)

Bristol Myers Squibb has disclosed Gains from Investment Securities across 17 years of filings, most recently posting -$21.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 320.0% year-over-year to -$21.0 million; the TTM figure through Mar 2026 stood at $590.0 million (up 11900.0% YoY), while the FY2025 annual figure was $351.0 million, changed N/A from the prior year.
• Gains from Investment Securities eased to -$21.0 million in Q1 2026, from $275.0 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for BMY reached as high as $336.0 million in Q2 2025 and fell as low as -$269.0 million in Q3 2023.
• The 5-year median for Gains from Investment Securities is -$5.0 million (2025), against an average of $23.8 million.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 690.91% — and 2024, when it sank 475.0%.
• A 5-year view of Gains from Investment Securities shows it stood at -$44.0 million in 2022, then surged by 690.91% to $260.0 million in 2023, then sank by 108.85% to -$23.0 million in 2024, then jumped by 1295.65% to $275.0 million in 2025, then plunged by 107.64% to -$21.0 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$21.0 million, $275.0 million, and $336.0 million for Q1 2026, Q4 2025, and Q2 2025 respectively.